

**HIKMA AND ARECOR ANNOUNCE EXCLUSIVE AGREEMENT TO DEVELOP AND COMMERCIALISE READY-TO-USE MEDICINE USING ARESTAT™ TECHNOLOGY**

*Product designed to provide safer, more immediate treatment option for patients*

**London and Cambridge, January 9, 2020** - Hikma Pharmaceuticals PLC (Hikma, Group / LSE: HIK / NASDAQ Dubai: HIK / OTC: HKMPY) (rated Ba1/stable Moody's and BB+/positive S&P), the multinational generic pharmaceutical company, and Arecor Ltd, the biopharmaceutical company advancing today's therapies to enable healthier lives, today announce they have entered into an exclusive agreement to co-develop a new, ready-to-use injectable medicine in the US through Hikma's affiliate, Hikma Pharmaceuticals USA Inc.

The product, which will be announced prior to launch, is being developed using Arecor's proprietary drug formulation technology platform Arestat™, which enhances the properties of approved therapeutic proteins and peptides to deliver new reformulations of existing, complex products. Hikma will seek approval for the product under the U.S. Food and Drug Administration's 505(b)(2) regulatory pathway, with filing expected in 2021.

"We are pleased to enter into this partnership with Arecor. This is another important step forward for Hikma in developing and commercialising complex medicines and delivery systems that benefit patients and position our business for continued long-term growth," said Riad Mishlawi, President, Hikma Injectables. "We are confident that Arecor's state-of-the-art development platform, combined with Hikma's strong manufacturing capabilities and excellent commercial team, with its broad relationships across US hospital systems, will bring an important new treatment option to patients and healthcare providers."

"We are proud to be working with Hikma," said Sarah Howell, Chief Executive Officer of Arecor. "Arecor has an excellent track record in developing ready-to-use (RTU) and ready-to-administer (RTA) medicines, which are becoming increasingly important to enable fast, safe and effective treatment of patients. Hikma has a strong and respected US hospital market presence and is focused on providing cost effective therapies which improve patient care and advance the delivery of medication. We look forward to the joint development of this first product as part of a broad collaboration with Hikma."

Under the terms of the royalty-based agreement, Arecor will receive an upfront payment and further payments on the achievement of development, regulatory and commercial milestones. Hikma will be responsible for the manufacture and commercialisation of the product. Arecor retains the right to develop and commercialise the product in certain markets outside the US.

**-ENDS-**

**For more information, please contact:**

**Hikma**

Susan Ringdal  
EVP, Strategic Planning and Global Affairs

+44 (0)20 7399 2760/ +44 7776 477050  
[uk-investors@hikma.com](mailto:uk-investors@hikma.com)

Steve Weiss  
US Communications and Public Affairs

+1 732 720 2830/ +1 732 788 8279  
[sweiss@hikma.com](mailto:sweiss@hikma.com)

**Areacor Limited**

Dr Sarah Howell  
Chief Executive Officer

Tel: +44 (0) 1223 426060  
Email: [sarah.howell@arecor.com](mailto:sarah.howell@arecor.com)

Susan Lowther  
Chief Financial Officer

Tel: +44 (0) 1223 426060  
Email: [susan.lowther@arecor.com](mailto:susan.lowther@arecor.com)

**Mo PR Advisory**

Mo Noonan

[www.mopr Advisory.com](http://www.mopr Advisory.com)  
Mob: +44 (0) 7876 444977  
Email: [mo@mopr Advisory.com](mailto:mo@mopr Advisory.com)

**Notes to Editors**

**About Hikma ([www.hikma.com](http://www.hikma.com))**

Hikma helps put better health within reach every day for millions of people in more than 50 countries around the world. For more than 40 years, we've been creating high-quality medicines and making them accessible to the people who need them. Headquartered in the UK, we're a global company with a local presence across the United States (US), the Middle East and North Africa (MENA) and Europe, and we use our unique insight and expertise to transform cutting-edge science into innovative solutions that transform people's lives. We're committed to our customers, and the people they care for, and by thinking creatively and acting practically, we provide them with a broad range of branded and non-branded generic medicines. Together, our 8,400 colleagues are helping to shape a healthier world that enriches all our communities. We are a leading licensing partner, and through our venture capital arm, are helping bring innovative health technologies to people around the world.

For more information, please visit [www.hikma.com](http://www.hikma.com)

**About Areacor ([www.arecor.com](http://www.arecor.com))**

Areacor Limited is a biopharmaceutical company transforming patient care by bringing innovative medicines to market. Through the enhancement of existing medicines using our Arestat™ technology, we are developing a broad portfolio of therapies as part of our proprietary pipeline and through partnerships with leading pharmaceutical and biotech companies. Our treatments for people living with chronic disease are designed to simplify patient care and improve medication adherence.

For further details please see our website, [www.arecor.com](http://www.arecor.com)